Replies to post #50548 on Biotech Values

[spartex]

REGN up $1.20 (8.78%) in early trading based on this P3 trial announcement. Market seems to like the news and shorts are probably doing some covering. :)

[DewDiligence]

REGN has phase-3 results of VEGF-Trap-Eye in AMD; CC Monday at 8:30am ET to find out what they are:

http://finance.yahoo.com/news/Regeneron-Schedules-November-prnews-3412679115.html?x=0&.v=1

The two phase-3 AMD trials started in 2007; the trial descriptions and some musings by me about the endpoints can be found in #msg-21785310.